Cephalon, Inc.  (CEPH)
Other Ticker:  
    Sector  Consumer Non Cyclical    Industry Legacy
   Industry Legacy
   Sector  Consumer Non Cyclical
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 88
 Employees -
 Revenues (TTM) (Millions $) 2,971
 Net Income (TTM) (Millions $) 553
 Cash Flow (TTM) (Millions $) 70
 Capital Exp. (TTM) (Millions $) -57

Cephalon, Inc.
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat human diseases. We currently focus our efforts in four core therapeutic areas: central nervous system ("CNS") disorders, pain, oncology and addiction. In addition to conducting an active research and development program, we market seven proprietary products in the United States and numerous products in various countries throughout Europe. Consistent with our core therapeutic areas, we have aligned our approximately 690-person U.S. field sales and sales management teams by area. In Europe, we have a sales and marketing organization numbering approximately 400 persons that supports our presence in nearly 20 European countries, including France, the United Kingdom, Germany, Italy and Spain.


Customers Net Income grew by CEPH's customers Net margin fell to 15.6 %

11.34 %

4.39 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        3.47% 
PFE        2.94% 
MRK        0.77% 
LLY        6.8% 
JNJ        3.11% 
ABT   -2.48%    
• View Complete Report

Easterly Government Properties Inc

EPS Growth Accelerates Sharply

For the most recent fiscal period earnings per share more than doubled by 300 % to $0.08 per share, followed by Sales increase of 11.65% to $65.00 millions, compared with the prior year period.

From the preceding quarter, eps more than doubled by 180.21 % from $0.03 per share and Sales decreased by -0.31% from $65.20 millions.

Mks Instruments Inc

Growth, Growth, Growth

Mks Instruments Inc showed respectable growth in the first quarter of 2021, where income surged by 76 % year on year to $2.20 per share and Sales increased by 29.53% to $693.90 millions.

Sequentially income improved by 5.24 % from $2.09 per share and Sales increased by 5.1 % from $660.20 millions.

Ptc Inc

Growth, Growth, Growth

Ptc Inc showed respectable growth in the second quarter of 2021, where earnings per share soared by 1433.33 % year on year to $0.92 per share and Sales increased by 28.42% to $461.79 millions.

Sequentially eps more than doubled by 360 % from $0.20 per share and Sales advanced by 7.63 % from $429.05 millions.

Patterson uti Energy Inc

Patterson Uti Energy Inc announced most recent fiscal period operating loss of $-117.527 millions

Patterson Uti Energy Inc reported disappointing most recent fiscal period, where Sales melted down by -45.97% to $240.93 millions and company posted loss per share to $-0.57, compared to $-2.28, in the same quarter a year ago.

compared to the previous quarter from $-0.57 per share and Sales advanced by 9.12 % from $220.80 millions.

Inogen Inc

Inogen Inc announced financial time frame ending Mar 31 2021 operating shortfall of $-2.132 millions

In the financial time frame ending Mar 31 2021 Inogen Inc decreased loss of $-0.03 per share compared to $-0.07 a year ago and improved from $-0.23 per share from the previous quarter.

Sales decreased by -1.76% to $86.93 millions from $88.49 millions in the same quarter a year ago and sequentially Sales improved by 17.51 % from $73.98 millions.


Cephalon's Segments
 Segment    34.4 % of total Revenue
 Segment    1.36 % of total Revenue
Total CNS
 Segment    45.51 % of total Revenue
 Segment    4.11 % of total Revenue
Generic OTFC
 Segment    0.82 % of total Revenue
 Segment    7.04 % of total Revenue
 Segment    1.86 % of total Revenue
Total Pain
 Segment    19.26 % of total Revenue
 Segment    21.74 % of total Revenue
 Segment    13.49 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cephalon does not provide revenue guidance.

Earnings Outlook
Inogen Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States 76.3 %
International 23.7 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

AWRE's Profile

Stock Price

AWRE's Financials

Business Description


Charts & Quotes

AWRE's News


AWRE's Competitors

Customers & Markets

Economic Indicators

AWRE's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071